Clinical trial / 1996
Oral magnesium showed no prophylactic benefit over placebo in migraine patients.
In an interim evaluation of 69 patients with 2 to 6 migraine attacks per month, 10 of 35 patients (28.6%) taking 10 mmol magnesium twice daily responded, compared to 10 of 34 (29.4%) taking placebo. Migraine days and attacks showed no difference between groups. Mild adverse events occurred in 45.7% of the magnesium group versus 23.5% with placebo, prompting trial discontinuation.
- Study type
- Multicenter, randomized, double-blind, placebo-controlled trial
- Who was studied
- 69 adults aged 18-64 with migraine
- What was measured
- Reduction of at least 50% in migraine attack intensity or duration in hours
THE PAPER
Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study.
Pfaffenrath V, Wessely P, Meyer C, Isler HR, Evers S, Grotemeyer KH, Taneri Z, Soyka D, Göbel H, Fischer M. Cephalalgia, 1996.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.